Engineered exosomes for future gene-editing therapy.

Haoyu Guo, Xin Huang
{"title":"Engineered exosomes for future gene-editing therapy.","authors":"Haoyu Guo, Xin Huang","doi":"10.12336/biomatertransl.2022.04.003","DOIUrl":null,"url":null,"abstract":"The RNA-guided clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated nuclease protein 9 (Cas9)-based technology is an advanced and popular gene-editing technology, which has shown great potential in treating genetic disorders in both animal models and even in clinical trials.1, 2 Many transportation strategies are available for delivery of the CRISPR-Cas9 system, among which Cas9 ribonucleoprotein (RNP) delivery has some competitive advantages over other options, such as faster editing onset speed with a reduced immune response and lower off-target activity.3, 4 However, the low in vivo delivery efficiency and poor tissue specificity of RNP delivery have limited further clinical applications.5 Writing in Science Advances, Wan et al.6 reported a previously-unidentified genome editing delivery system, named exosomeRNP which transported RNPs within exosomes extracted from hepatic stellate cells via electroporation. The exosomeRNP exhibited effective intracellular and intercellular delivery and accumulation of RNPs to hepatocytes in vitro and in vivo, resulting in significant therapeutic effects in several hepatic diseases. The system was tested in mouse models of acute liver injury, chronic liver fibrosis, and hepatocellular carcinoma by targeting p53 upregulated modulator of apoptosis, cyclin-E1, and K(lysine) acetyltransferase-5, respectively, providing a potential strategy for high-efficiency, precise and tissue-specific gene editing in liver diseases.","PeriodicalId":58820,"journal":{"name":"Biomaterials Translational","volume":"3 4","pages":"240-242"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/47/10/bt-03-04-240.PMC9947735.pdf","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomaterials Translational","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12336/biomatertransl.2022.04.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

The RNA-guided clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated nuclease protein 9 (Cas9)-based technology is an advanced and popular gene-editing technology, which has shown great potential in treating genetic disorders in both animal models and even in clinical trials.1, 2 Many transportation strategies are available for delivery of the CRISPR-Cas9 system, among which Cas9 ribonucleoprotein (RNP) delivery has some competitive advantages over other options, such as faster editing onset speed with a reduced immune response and lower off-target activity.3, 4 However, the low in vivo delivery efficiency and poor tissue specificity of RNP delivery have limited further clinical applications.5 Writing in Science Advances, Wan et al.6 reported a previously-unidentified genome editing delivery system, named exosomeRNP which transported RNPs within exosomes extracted from hepatic stellate cells via electroporation. The exosomeRNP exhibited effective intracellular and intercellular delivery and accumulation of RNPs to hepatocytes in vitro and in vivo, resulting in significant therapeutic effects in several hepatic diseases. The system was tested in mouse models of acute liver injury, chronic liver fibrosis, and hepatocellular carcinoma by targeting p53 upregulated modulator of apoptosis, cyclin-E1, and K(lysine) acetyltransferase-5, respectively, providing a potential strategy for high-efficiency, precise and tissue-specific gene editing in liver diseases.

Abstract Image

用于未来基因编辑治疗的工程外泌体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.70
自引率
0.00%
发文量
9
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信